Cargando…

Baricitinib Lipid-Based Nanosystems as a Topical Alternative for Atopic Dermatitis Treatment

Atopic dermatitis (AD) is a chronic autoimmune inflammatory skin disorder which causes a significant clinical problem due to its prevalence. The ongoing treatment for AD is aimed at improving the patient’s quality of life. Additionally, glucocorticoids or immunosuppressants are being used in systemi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garrós, Núria, Bustos-Salgados, Paola, Domènech, Òscar, Rodríguez-Lagunas, María José, Beirampour, Negar, Mohammadi-Meyabadi, Roya, Mallandrich, Mireia, Calpena, Ana C., Colom, Helena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305096/ https://www.ncbi.nlm.nih.gov/pubmed/37375841 http://dx.doi.org/10.3390/ph16060894

Ejemplares similares

Baricitinib Liposomes as a New Approach for the Treatment of Sjögren’s Syndrome
por: Garrós, Núria, et al.
Publicado: (2022)

Assessing the Solubility of Baricitinib and Drug Uptake in Different Tissues Using Absorption and Fluorescence Spectroscopies
por: Mohammadi-Meyabadi, Roya, et al.
Publicado: (2022)

Topical Pioglitazone Nanoformulation for the Treatment of Atopic Dermatitis: Design, Characterization and Efficacy in Hairless Mouse Model
por: Espinoza, Lupe Carolina, et al.
Publicado: (2020)

HPV Lesions and Other Issues in the Oral Cavity Treatment and Removal without Pain
por: El Moussaoui, Salima, et al.
Publicado: (2021)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Semi-Solid Dosage Forms Containing Pranoprofen-Loaded NLC as Topical Therapy for Local Inflammation: In Vitro, Ex Vivo and In Vivo Evaluation
por: Ahmadi, Negar, et al.
Publicado: (2023)

Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience
por: ROGNER, Danielle, et al.
Publicado: (2022)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

In Vitro Approaches to Explore the Anticancer Potential of One Natural Flavanone and Four Derivatives Loaded in Biopolymeric Nanoparticles for Application in Topical Delivery Treatments
por: Bustos-Salgado, Paola, et al.
Publicado: (2023)

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Reich, Kristian, et al.
Publicado: (2020)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
por: de Bruin-Weller, Marjolein S., et al.
Publicado: (2022)

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial
por: Wollenberg, A., et al.
Publicado: (2021)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

Topical tacrolimus as treatment of atopic dermatitis
por: Furue, Masutaka, et al.
Publicado: (2009)

Topical steroid addiction in atopic dermatitis
por: Fukaya, Mototsugu, et al.
Publicado: (2014)

Topical Therapy in Atopic Dermatitis in Children
por: Sathishkumar, Dharshini, et al.
Publicado: (2016)

Tolerability of Topical Treatments for Atopic Dermatitis
por: Draelos, Zoe D., et al.
Publicado: (2019)

What’s New in Topicals for Atopic Dermatitis?
por: Kleinman, Elana, et al.
Publicado: (2022)

Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
por: Radi, Giulia, et al.
Publicado: (2021)

Process utilities for topical treatment in atopic dermatitis
por: Retzler, Jenny, et al.
Publicado: (2019)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
por: Wan, Huiying, et al.
Publicado: (2022)

Endogenous Antioxidant Cocktail Loaded Hydrogel for Topical Wound Healing of Burns
por: Soriano, José L., et al.
Publicado: (2020)

Caspofungin-Loaded Formulations for Treating Ocular Infections Caused by Candida spp.
por: Pérez-González, Noelia, et al.
Publicado: (2023)

Topical steroid therapy in atopic dermatitis in theory and practice
por: Jeziorkowska, Renata, et al.
Publicado: (2015)

Staphylococcus aureus resistance to topical antimicrobials in atopic dermatitis
por: Bessa, Giancarlo Rezende, et al.
Publicado: (2016)

Atopic dermatitis: a review of topical nonsteroid therapy
por: Papier, Ariana, et al.
Publicado: (2018)

Topical Tacrolimus for the Treatment of Atopic Dermatitis with Truncal Lesion
por: Ko, Hyun Chang, et al.
Publicado: (2018)

Topical treatment with SPHINGOLIPIDS and GLYCOSAMINOGLYCANS for canine atopic dermatitis
por: Marsella, Rosanna, et al.
Publicado: (2020)

Novel Therapeutic Strategies in the Topical Treatment of Atopic Dermatitis
por: Pinto, Lorenzo Maria, et al.
Publicado: (2022)

From the Cochrane Library: Topical Tacrolimus for Atopic Dermatitis
por: Hamp, Austin, et al.
Publicado: (2021)

Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence
por: Napolitano, Maddalena, et al.
Publicado: (2020)

Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies
por: Buhl, Timo, et al.
Publicado: (2021)

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2022)

Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials
por: Katoh, Norito, et al.
Publicado: (2022)

Characterization and In Vivo Anti-Inflammatory Efficacy of Copal (Dacryodes peruviana (Loes.) H.J. Lam) Essential Oil
por: Espinoza, Lupe Carolina, et al.
Publicado: (2022)

The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials
por: Yosipovitch, Gil, et al.
Publicado: (2022)

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2023)

Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
por: Thyssen, Jacob P., et al.
Publicado: (2023)

Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials
por: Wollenberg, Andreas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k9gv61f202143nvfbckkio2041